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An essential role for TAK1 in the contact hypersensitivity
response
Yan G Zhao1,2, Yunqi Wang2, Weidong Hao1 and Yisong Y Wan2
Contact hypersensitivity (CHS) is a delayed-type hypersensitivity that can be induced by haptens, such as 2,4-dinitrofluorobenzene
(DNFB). Innate and adaptive immunities are both important for the development of CHS. To treat CHS-related diseases, such as
allergic contact dermatitis, a disease prevalent in industrialized countries, ways of interfering with improper immune function during
CHS responses need to be identified. Transforming growth factor-b-activated kinase-1 (TAK1), a member of mitogen-activated protein
kinase kinase kinase family, is important for both innate and adaptive immunities. We thus hypothesized that the CHS response could
be inhibited by interfering with TAK1 activity. Using a mouse model in which TAK1 deletion can be locally induced, we observed that
TAK deficiency led to an impaired CHS response and was associated with defective T-cell expansion, activation and interferon (IFN)-c
production. In addition, we investigated the effect of deleting TAK1 specifically in dendritic cells (DC) on the CHS response. We found
that when TAK1 is deficient in DC, the CHS response was abolished and hapten-elicited T-cell responses were defective. Collectively,
this study demonstrates an essential role of TAK1 in the induction of CHS and suggests that targeting TAK1 could be a viable approach
to treat CHS.
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INTRODUCTION
Allergic contact dermatitis is one of the most common occu-
pational diseases in industrialized countries, and it has large socio-
economic impact.1,2 Knowledge of the pathophysiology of human
allergic contact dermatitis has been obtained mainly from studies
using murine models of contact hypersensitivity (CHS) to strong
haptens, such as 2,4-dinitrofluorobenzene (DNFB). With a single
contact, DNFB is able to elicit a CHS response in the skin. In mouse
models, CHS is induced in two phases.3 The first phase is the
sensitization phase that is induced by painting a small area of
abdominal or back skin with a hapten. During the sensitization
phase, a hapten binds to endogenous proteins in the skin, alters
the antigenicity of these proteins and activates professional antigen-
presenting dendritic cells (DC) residing in the skin. Proteins with
newly arisen antigenic specificities are processed by epidermal DCs,
Langerhans cells and dermal DCs.4,5 Activated hapten-bearing DCs
migrate to the draining lymph nodes (DLN), where antigen-specific
CD4 and CD8 T cells are primed.6 The second phase in the
development of CHS is the elicitation phase, which is induced by
epicutaneous hapten challenge 5 days after the initiation phase at a
previously unexposed site, usually the ear skin. In this phase, T
lymphocytes that were previously primed during the initiation
phase are activated in the dermis and the epidermis in response
to the challenge; they trigger an inflammatory process through
interferon (IFN)-c production and cytotoxicity toward keratino-
cytes.7,8 Both DCs and T cells play critical roles in the development
of CHS. Therefore, efficient ways of inhibiting DC and T-cell func-
tion to treat CHS need to be developed.
Transforming growth factor-b-activated kinase-1 (TAK1) is a ser-
ine/threonine kinase belonging to the mitogen-activated protein
kinase kinase kinase family. Various stimuli can activate TAK1.9,10
Once activated, TAK1 promotes downstream signaling molecules
including NF-kB,11,12 c-Jun N-terminal kinase MAPK and p38
MAPK.13 TAK1 is essential to control the survival, differentiation
and function of innate and adaptive immune cells and thus also has
an effect on related responses.9,12,14 Therefore, we hypothesize that we
can inhibit the CHS response by interfering with TAK1 function.
In this study, we tested this hypothesis by disrupting TAK1 function
both locally and specifically in DCs. We demonstrated that normal func-
tion of TAK1 during the initiation phase is required for the CHS response
and corresponding T-cell activation, expansion and effector function. In
addition, we showed that inhibiting TAK1 function specifically in DC is
critical for the development of CHS and T-cell activation. Therefore, we
have provided evidence that TAK1 is essential for the CHS response and
that local or DC-specific targeting of TAK1 may be a viable approach to
treat CHS and related delayed-type hypersensitivity diseases.
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Figure 1 Defective CHS response to DNFB in TMA-treated ER-TAK1fl/fl mice. (a) On day 1, ER-TAK1fl/fl mice were painted with DNFB mixed with (1) or without (2)
TMA on their dehaired back skin. Mice were challenged with DNFB on the left ear skin on day 6. Ear thickness was measured before (open bar) and 48 h after (solid bar)
the challenge and plotted (lower left panel). The changes in ear thickness (D ear thickness) were also calculated and plotted (lower right panel). Mean6SD values of
four mice are shown, and the P value is indicated. (b) ER-TAK1fl/fl mice were painted with TMA (1) or not (2). The painted skin were excised and subjected to PCR
analysis for TAK-deleted alleles (DTAK1) and Cre (served as internal control). (c) A CHS response was induced in indicated mouse strains with or without TMA as
shown in the scheme (left panel). The ear thickness was measured before and after challenge as described in (a), andD ear thickness was calculated and plotted (right
panel). Mean6SD values of three mice are shown, and the P value is indicated. CHS, contact hypersensitivity; DNFB, 2,4-dinitrofluorobenzene; TAK1, transforming
growth factor-b-activated kinase-1; TMA, tamoxifen.
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MATERIALS AND METHODS
Mice
TAK1fl/fl has been described previously.12 CD11c-Cre mice were
kindly provided by B. Reizis (Columbia University, New York,
USA). ER-Cre mice were kindly provided by T. Ludwig (Columbia
University). All mice were on a C57BL/6 background and were kept
under specific pathogen-free conditions in the animal care facility at
the University of North Carolina at Chapel Hill. All mouse experi-
ments were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Hapten sensitization and elicitation of CHS
Mice were sensitized to DNFB (Sigma-Aldrich, St Louis, MO, USA) on
day 1 by applying 25 ml 0.5% DNFB topically on dehaired back skin
(sensitization phase). On day 6, sensitized mice were challenged topi-
cally with 10 ml 0.25% DNFB on the left ear (elicitation phase). To
delete the TAK1 gene in ER-TAK1fl/fl mice, 50 mg tamoxifen (Sigma-
Aldrich) was painted together with DNFB solution during the sens-
itization phase. Ear thickness was assessed with an electronic digital
caliper (VWR, Radnor, PA, USA) before challenge and 48 h after
challenge. The degree of the CHS response was determined by the
increase in ear thickness 48 hours post-challenge.
Staining for surface markers and Foxp3
Lymphocytes were isolated from the auricular DLN. Various surface
markers and intracellular Foxp3 were stained with cocktails of fluor-
escence-conjugated antibodies according to the manufacturer’s pro-
tocols (eBioscience, San Diego, CA, USA).
Stimulation of cytokine production and intracellular cytokine
staining
Lymphocytes were isolated from DLN and stimulated with 50 ng/ml
phorbol myristate acetate (Sigma-Aldrich) and 1 mM of ionomycin
(Sigma-Aldrich) for 4 h in the presence of 2 mg/ml Brefeldin A (Sigma-
Aldrich). The cells were stimulated in Bruff’s T-cell medium
(Sigma-Aldrich) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin under typical cell culture conditions
(37 uC, 5% CO2). Different surface markers and intracellular cytokines
were stained with cocktails of fluorescence-conjugated antibodies as
per the manufacturer’s protocols (BD Bioscience, San Jose, CA, USA).
Flow cytometry analysis
Fluorescence-conjugated antibodies, including CD4-Pacific blue,
CD8-PE-CY7, CD44-FITC, IFN-c-FITC, IL-4-APC, CD62L-APC,
Foxp3-PE and IL-17-PE, were purchased from eBioscience. Flow cyto-
metry analysis of labeled cells was performed on an LSRII (Becton
Dickinson, San Jose, CA, USA) or a CyAn (Beckman Coulter; Dako
Cytomation, Fort Collins, CO, USA).
Statistical analysis
Data from at least three sets of samples were used for statistical
analysis. Statistical significance was calculated by Student’s t-test. A
P value of less than 0.05 was considered significant.
RESULTS
Local disruption of TAK1 inhibited the development of CHS
While TAK1 has been shown to be important for the generation and
function of various cell types mediating innate and adaptive immun-
ity,15 its role in the development of inflammatory diseases remains
poorly understood. We hypothesized that TAK1 is critical in the
development of the CHS response and that this response can be inhib-
ited by interfering with TAK1 function. We thus investigated whether
TAK1 is required for CHS induction by DNFB. We crossed mice
bearing loxP-flanked TAK1 alleles12 with ER-Cre mice to generate
ER-TAK1fl/fl mice. In ER-Cre mice, constitutively expressed Cre pro-
tein is activated only when tamoxifen is provided.16 Therefore, we can
induce deletion of TAK1 in ER-TAK1fl/fl mice at any time by providing
tamoxifen as described previously.17 We topically applied DNFB
mixed with 50 mg tamoxifen to the dehaired back of ER-TAK1fl/fl mice
to delete TAK1 during the sensitization phase of the CHS response
(Figure 1a, top panel). Following DNFB treatment on the ear skin in
the elicitation phase, a CHS response was elicited, and the degree of the
response was assessed by measuring ear thickness. In response to this
treatment, the ear thickness of mock-treated ER-TAK1fl/fl mice
increased substantially, indicating severe skin inflammation. By con-
trast, the ears of tamoxifen-treated ER-TAK1fl/fl mice failed to swell
(Figure 1a, lower panel). TAK1 deletion was detected in the skin of
ER-TAKfl/fl mice treated with tamoxifen but not those treated with
vehicle alone (Figure 1b). Therefore, local disruption of TAK1 during
the initiation phase inhibited the development of CHS.
To confirm that the above finding was not due to a defect in the
ER-TAK1fl/fl mouse itself or tamoxifen application, we elicited a
DNFB-induced CHS response in ER-TAK1fl/fl mice without tamoxi-
fen treatment and in wild-type mice with or without tamoxifen treat-
ment. DNFB efficiently induced a CHS response in both ER-TAK1fl/fl
mice and wild-type mice treated with tamoxifen (Figure 1c).
Therefore, the defective CHS response observed in tamoxifen-treated
ER-TAK1fl/fl mice resulted from the TAK1 deficiency.
T-cell activation, expansion and effector function require intact
TAK1 during CHS response
To elucidate the cellular mechanisms underlying the requirement of
TAK1 for a CHS response, we investigated whether T-cell function
was affected, as T cells are known to be the critical cell type mediating
the CHS response.18 There was no significant difference in the percen-
tages of CD4 and CD8 T cells from peripheral lymph nodes and spleens
between tamoxifen and mock-treated ER-TAK1fl/fl mice, suggesting
that application of 50 mg tamoxifen on skin did not cause general defect
in T-cell numbers (Figure 2a). Auricular lymph nodes of both draining
side (DLN) and non-draining side (control lymph node (CLN)) for
DNFB-treated ears were collected, and the numbers of total lympho-
cytes in these lymph nodes were determined. The numbers of total
lymphocytes, CD4 and CD8 T cells in CLN did not change upon
DNFB treatment in both tamoxifen-treated and non-tamoxifen-treated
ER-TAK1fl/fl mice (Figure 2b). However, the numbers of total lym-
phocytes, CD4 and CD8 T cells in DLN for DNFB-treated mice were
increased compared with those in non-DNFB-treated ER-TAK1fl/fl mice
Figure 2 T cells failed to expand in TMA-treated ER-TAK1fl/fl mice during a CHS response. (a) Flow cytometry analysis of CD4 and CD8 T cells in PLN and spleens from ER-
TAK1fl/fl mice with or without TMA treatment. (b) Forty-eight hours after challenge, the auricular lymph nodes of DLN (solid bar) and CLN (open bar) for DNFB-treated ears
were collected and the numbers of total lymphocytes were counted and plotted. The numbers of total lymphocytes and CD4 and CD8 T cells were calculated and plotted
based on the percentages of each population as determined by flow cytometry analysis. (c) Foxp3 expression was detected by intracellular staining and flow cytometry.
Numbers above the bracketed lines indicate the percentage of Foxp31 cells among the CD4 population (left panel). The absolute numbers of Foxp31 cells from DLN (solid
bar) and CLN (open bar) were calculated and plotted. Mean6SD values of four mice are shown, and the P value is indicated. CHS, contact hypersensitivity; CLN, control
lymph node; DLN, draining lymph node; PLN, peripheral lymph node; TAK1, transforming growth factor-b-activated kinase-1; TMA, tamoxifen.
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(Figure 2b), consistent with the observed ear inflammation and swell-
ing. By contrast, such an increase did not occur in tamoxifen-treated
ER-TAK1fl/fl mice (Figure 2b). Similarly, we observed that the percent-
age and the numbers of Foxp31 CD4 T cells increased in mock-treated
but not in tamoxifen-treated ER-TAK1fl/fl mice (Figure 2c). Therefore,
interfering with TAK1 function during the initiation phase abrogated
the increase in T-cell numbers that is normally associated with inflam-
mation during a CHS response.
Hapten-specific CD8 T cells are recognized as the main effector cells
that mediate CHS.19,20 CD4 T cells cooperate with CD8 T cells21 and,
in certain instances, mediate murine CHS responses to strong hap-
tens.22 We further investigated whether T-cell activation and effector
cytokine production were affected by TAK1 deletion during a CHS
response. We found that while CD4 and CD8 T cells displayed an
activated phenotype (CD62LlowCD44high) in mock-treated ER-
TAK1fl/fl mice (Figure 3a and b), such activation did not occur in
tamoxifen-treated ER-TAK1fl/fl mice (Figure 3a and b), suggesting
that TAK1 is required for T-cell activation during the CHS response.
The CHS response induced by DNFB is controlled by IFN-c pro-
duced by CD8 T cells and, to a lesser extent, IFN-c, IL-4 and IL-17
produced by Th1, Th2 and Th17 T cells, respectively. We assessed
whether interfering with TAK1 function impacted cytokine produc-
tion by T cells. Indeed, while a great number of IFN-c-producing CD8
T cells was detected in mock-treated ER-TAK1fl/fl mice with ongoing
CHS (Figure 3c), smaller numbers of IFN-c-producing CD8 T cells
were found in tamoxifen-treated ER-TAK1fl/fl mice (Figure 3c).
Similarly, smaller percentages of IFN-c-producing Th1 cells were
found in tamoxifen-treated mice than in mock-treated ER-TAK1fl/fl
mice (Figure 3d). Therefore, TAK1 is required for normal levels of
cytokine expression in effector T cells during CHS response.
TAK1 function in DC is essential for CHS response
Hapten-induced T-cell activation and CHS requires intact function of
innate cells, such as cutaneous DC.4,23 We therefore hypothesized that
the requirement of TAK1 in CHS response could be attributed, at least
in part, to its essential role in regulating DC function. To test this
hypothesis, we crossed TAK1fl/fl mice with CD11c-Cre mice to gen-
erate CD11c-TAK1fl/fl mice, which allowed for deletion of the TAK1
gene specifically in CD11c1 DC, and elicited a DNFB-induced CHS
response in CD11c-TAK1fl/fl and CD11c-TAK1fl/wt mice. While a CHS
response was efficiently induced in CD11c-TAK1fl/wt mice with ear
swelling upon challenge, CD11c-TAK1fl/fl mice failed to develop CHS
(Figure 4a). The floxed TAK1 allele was efficiently deleted in sorted
CD11c1 cells but not in CD41 cells (Figure 4b), indicating an efficient
TAK1 deletion specifically in the DC population.
Intact TAK1 in DC is critical for T-cell function during CHS
development
We further investigated whether T-cell function was affected in
CD11c-TAK1fl/fl mice during CHS development. Our analysis
revealed that the numbers of CD4, CD8 and Foxp3-expressing CD4
cells were elevated in CD11c-TAK1fl/wt mice with ongoing CHS res-
ponses. However, these increases were abolished in CD11c-TAK1fl/fl
mice given the same treatment (Figure 5). Therefore, intact function of
TAK1 in the CD11c1 DC population is important to promote T-cell
expansion during CHS response. In addition, we observed that T-cell
activation was abolished in CD11c-TAK1fl/fl mice following CHS
induction. The percentages of activated (CD62LlowCD44high) CD4
and CD8 T cells of the DLN from CD11c-TAK1fl/wt mice increased
significantly after CHS induction. However, such an increase did not
occur in similarly treated CD11c-TAK1fl/fl mice (Figure 6a and b),
suggesting an important role of TAK1 in DC for T-cell activation
during CHS. Furthermore, we assessed the cytokine production of T
cells in CD11c-TAK1fl/wt mice and CD11c-TAK1fl/fl mice undergoing
a CHS response. Consistent with T-cell activation status, although a
Figure 3 Lack of activation and cytokine production of CD4 and CD8 T cells in TMA-treated ER-TAK1fl/fl mice. Flow cytometry analysis of CD62L and CD44 expression
on CD4 (a) and CD8 (b) T cells in DLN from indicated mice 48 h after challenge (left panels). The percentages of the CD62Llow CD44high effector T-cell population were
plotted (right panels). Mean6SD values of four mice are shown, and the P value is indicated. (c) IFN-c and IL-17 production by CD8 cells in the DLN of indicated mice
(left panels). The frequencies (%) of IFN-c-producing CD8 cells obtained from four independent experiments are shown. Mean6SD values are shown and the P value
is indicated. (d) IFN-c, IL-4 and IL-17 production in CD4 cells in DLN from indicated mice were detected by intracellular staining. Representative results of four
independent experiments are shown. CLN, control lymph node; DLN, draining lymph node; IFN, interferon; TAK1, transforming growth factor-b-activated kinase-1;
TMA, tamoxifen.
Figure 4 Abolished CHS response in CD11c-TAK1fl/fl mice. (a) On day 1, the
dehaired back skins of CD11c-TAK1fl/fl and CD11c-TAK1fl/wt mice were painted
with DNFB. Mice were then challenged with DNFB on day 6. Before (open bar)
and 48 h after (solid bar) challenge, ear thickness was measured and plotted (top
panel). The D ear thickness was also calculated and plotted (lower panel).
Mean6SD values of four mice are shown, and the P value is indicated. (b)
CD11c1 and CD41 cells were purified from CD11c-TAK1fl/wt mice. PCR analysis
for the floxed-TAK allele (TAK1fl) and WT TAK1 allele (TAK1wt) (which served as
an internal control) was performed. CHS, contact hypersensitivity; DNFB, 2,4-
dinitrofluorobenzene; TAK1, transforming growth factor-b-activated kinase-1;
WT, wild type.
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large percentage of IFN-c-producing CD8 T cells were found in the
DLN of CD11c-TAK1fl/wt mice, CD8 T cells from CD11c-TAK1fl/fl
mice failed to increase IFN-c production (Figure 6c). Similarly, CD4
T cells in CD11c-TAK1fl/fl mice did not produce elevated levels of
IFN-c upon CHS induction (Figure 6d).
Collectively, this study demonstrated that intact function of TAK1
is critical for hapten-elicited activation and effector function of T cells
and the development of a CHS response. Furthermore, this function of
TAK1 can be ascribed at least in part to its critical role in regulating DC
function.
DISCUSSION
The relationship between TAK1 and immune function was originally
revealed by studies on Drosophila.24 Subsequently, TAK1 was shown to
be required for both innate and adaptive immunity in mammals.9,12,14
Previous studies have indicated that TAK1 is involved in the develop-
ment of inflammatory diseases, such as rheumatoid arthritis.25,26
Targeting TAK1 function may therefore be a viable approach to treat-
ing inflammatory diseases. CHS, a murine model for studying allergic
contact dermatitis, is characterized as a classic T cell-mediated
immune response.18 Whether TAK1 was functionally involved in
CHS development was not previously addressed. Our current study
shows for the first time that CHS induction and T-cell activation by
DNFB are dependent on TAK1.
During the elicitation phase of CHS, re-exposure of sensitized
mice to DNFB induces quantitative and qualitative alterations in
T-lymphocyte responses. Quantitatively, T cells proliferate and
increase in numbers in DLN.27 Qualitatively, T cells display an
Figure 5 T cells failed to expand during the CHS response in CD11c-TAK1 fl/fl mice. (a) Forty-eight hours after challenge, lymphocytes from DLN (solid bar) and CLN
(open bar) were collected from the indicated mouse strains, and the numbers of total lymphocytes were counted. CD4 and CD8 T-cell numbers were calculated and
plotted based on the percentage of each population as determined by flow cytometry analysis and the total numbers of lymphocytes. (b) Foxp3 expression was
detected by intracellular staining and flow cytometry. Numbers above the bracketed lines indicate the percentages of Foxp31 cells among the CD4 population (left
panels). The absolute numbers of Foxp31 cells from DLN (solid bar) and CLN (open bar) were calculated and plotted (right panel). Mean6SD values of four mice are
shown, and the P value is indicated. CHS, contact hypersensitivity; CLN, control lymph node; DLN, draining lymph node; TAK1, transforming growth factor-b-activated
kinase-1.
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activated phenotype by downregulating CD62L expression and
upregulating CD44 expression28 and producing IFN-c.6 We found
that interfering with TAK1 function affected T-cell function both
quantitatively and qualitatively. First, T-cell numbers failed to increase
in response to CHS response when TAK1 was disrupted (Figure 2b).
Peripheral T-cell survival has been shown to be dependent on TAK1.12
However, the percentages of CD4 and CD8 T cells from peripheral
lymph node, spleen and CLN did not decrease in tamoxifen-treated
ER-TAK1fl/fl mice during a CHS response (Figure 2a and b), indicating
that local administration of tamoxifen did not cause systemic deple-
tion of T cells. Thus, the lack of T-cell expansion in DLN of mice with
inhibited TAK1 is likely due to unresponsiveness to DNFB elicitation
rather than to a defect in T-cell survival caused by TAK1 deletion. In
agreement with this notion, our study showed that T cells failed to
become activated or to produce IFN-c when TAK1 was absent.
Multiple mechanisms may account for this observation. The prev-
iously described requirement of TAK1 for T-cell function12 could
explain our findings. In addition, defective innate function due to
TAK1 disruption may also contribute to T-cell unresponsiveness.
The induction of a CHS response relies on the activation, matura-
tion, antigen presentation and migration of innate immune cells.29
TAK1 may be important for these functions during the initiation of
CHS. In ER-TAK1fl/fl mice, tamoxifen application on skin induced
TAK1 deletion in various cell types, including stromal cells, but par-
ticularly in cutaneous DC, which are considered to play a central role
in the initiation of responses to haptens.29 To specifically study the
influence of TAK1 on DCs, we generated CD11c-TAK1fl/fl mice to
knock out the TAK1 gene specifically in CD11c1 cells, which are
mainly DC. Using this mouse model, we found that TAK1 function
in DC is critical for the induction of CHS and T-cell responses
(Figures 4a, 5a and 6). Although we have provided convincing genetic
evidence to support the notion that TAK1 is essential for DC function
during hapten-elicited CHS responses, the underlying mechanisms
remain to be addressed. One possible explanation is that TAK1 plays
an important role in the Toll-like receptor-induced NF-kB activa-
tion30,31 that is critical for DC functions, including migration, survival
and antigen processing and presentation.32 Given that the Toll-like
receptor (TLR) are thought to be indispensable for CHS develop-
ment,23 one mechanism by which TAK1 regulates DC function during
CHS may be through a Toll-like receptor pathway. In addition, the
migratory ability of DC might be affected by TAK1 deletion because
the expression of chemokine ligands, including ccl2, ccl7 and ccl5, was
strongly suppressed in TAK1 null cells.33 However, whether TAK1
deficiency affects the maturation, antigen presentation ability or cyto-
kine production of DC warrants further study.
Regulatory T cells potently suppress innate and adaptive immune
cells34 to dampen immune responses and maintain homeostasis. For
example, regulatory T cells can be induced by foreign antigen35 to limit
the inflammatory response in the skin.36 It is possible that the impaired
CHS response we observed in mice with defective TAK1 function was
due to increased immune suppression mediated by Foxp3-expressing
regulatory T cells. However, our findings suggested that this may not be
the case because the percentage and numbers of Foxp31 cells in tamox-
ifen-treated ER-TAK1fl/fl mice and in CD11c-TAK1fl/fl mice failed to
increase during the CHS response, unlike in the control mice (Figure 2c
and 4b). This finding suggests that TAK1 is critically involved in CHS
responses through a regulatory T cell-independent mechanism.
In conclusion, our study showed for the first time that TAK1 is
critical for CHS development. Mechanistically, TAK1 is essential for
the functions of both innate immunity mediated by DC and adaptive
immunity mediated by T cells in the elicitation of a CHS response.
Therefore, local or DC-specific targeting of a TAK1 deletion may serve
as a viable approach to treating CHS-type immune diseases.
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